Last reviewed · How we verify
Evaluation of Transfer From Subutex or Other Treatment for Opioid Drug Dependence to Suboxone: Acceptability, Safety and Impact on Medication Dispensing
The purpose of this study is to evaluate the acceptability and safety of switching to Suboxone® (buprenorphine plus naloxone) and the effect of the switch on medication dispensing. Subjects, for whom a therapy with Suboxone® is indicated and planned prior to study enrollment and who are willing to participate, will initiate therapy on Day 1 of the study. The dosage will be adjusted between Day 2 to 7 depending on patient's needs and determined by the treating physicians in accordance with the SmPC of Suboxone®. Data will be collected at baseline, day 1 til 7, the end of weeks 2 and 4 and monthly up to the end of Month 12.
Details
| Lead sponsor | Indivior Inc. |
|---|---|
| Status | COMPLETED |
| Enrolment | 339 |
| Start date | 2008-05 |
| Completion | 2011-04 |
Conditions
- Opioid-Related Disorders
- Opiate Dependence
- Drug Abuse
Interventions
- buprenorphine/naloxone
Primary outcomes
- Retention Rate — month 6, month 12
The primary objective of this study was to determine the retention rate of patients after 6 and 12 months of treatment with buprenorphine/naloxone measured by the percentage of patients remaining in the study
Countries
Austria